{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T21:20:06Z","timestamp":1791580806960,"version":"4.3.4"},"reference-count":27,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","msard-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.msard.2026.106998","type":"journal-article","created":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T00:30:54Z","timestamp":1768350654000},"page":"106998","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Extended interval dosing of off-label rituximab in multiple sclerosis: A real-world retrospective analysis of clinical efficacy and safety"],"prefix":"10.1016","volume":"107","author":[{"given":"Sepideh","family":"Paybast","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melika","family":"Jameie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zohreh","family":"Tajabadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehdi","family":"Azizmohammad Looha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatemeh A.","family":"Basti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mobina","family":"Amanollahi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kiana","family":"Amani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marziyeh","family":"Mousavi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seyed Ehsan","family":"Mohammadianinejad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4894-4022","authenticated-orcid":false,"given":"Mohammad Hossein","family":"Harirchian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.msard.2026.106998_bib0001","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.661882","article-title":"Rituximab in multiple sclerosis: are we ready for regulatory approval?","volume":"12","author":"Brancati","year":"2021","journal-title":"Front. Immunol."},{"issue":"5","key":"10.1016\/j.msard.2026.106998_bib0002","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000200152","article-title":"Efficacy of rituximab outlasts B-Cell repopulation in multiple sclerosis","volume":"10","author":"Claverie","year":"2023","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"10.1016\/j.msard.2026.106998_bib0003","doi-asserted-by":"crossref","DOI":"10.1002\/acn3.70142","article-title":"Comparative effect of standard versus extended interval dosing of rituximab or ocrelizumab in multiple sclerosis","author":"El Ayoubi","year":"2025","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"10.1016\/j.msard.2026.106998_bib0004","first-page":"15","article-title":"Hypogammaglobulinemia and infections in patients with multiple sclerosis treated with anti-CD20 treatments: a systematic review and meta-analysis of 19,139 multiple sclerosis patients","author":"Elgenidy","year":"2024","journal-title":"Front. Neurol."},{"issue":"1","key":"10.1016\/j.msard.2026.106998_bib0005","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1186\/s12883-021-02218-4","article-title":"Rituximab and risk of COVID-19 infection and its severity in patients with MS and NMOSD","volume":"21","author":"Esmaeili","year":"2021","journal-title":"BMC. Neurol."},{"key":"10.1016\/j.msard.2026.106998_bib0006","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2025.106400","article-title":"Early extended interval dosing of rituximab in multiple sclerosis: a comparative cohort study on efficacy and safety","volume":"97","author":"Fossum","year":"2025","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"8","key":"10.1016\/j.msard.2026.106998_bib0007","doi-asserted-by":"crossref","first-page":"3469","DOI":"10.1007\/s10072-025-08098-7","article-title":"Clinical and radiological activity after extended interval and standard interval dosing of ocrelizumab in multiple sclerosis: a systematic review and meta-analysis","volume":"46","author":"Ghajarzadeh","year":"2025","journal-title":"Neurol. Sci."},{"issue":"9","key":"10.1016\/j.msard.2026.106998_bib0008","doi-asserted-by":"crossref","first-page":"2859","DOI":"10.1111\/ene.15891","article-title":"Ocrelizumab extended-interval dosing in multiple sclerosis during <scp>SARS-CoV<\/scp>-2 pandemic: a real-world experience","volume":"30","author":"Guerrieri","year":"2023","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/j.msard.2026.106998_bib0009","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2022.103798","article-title":"Hypogammaglobulinemia, infections and COVID-19 in people with multiple sclerosis treated with ocrelizumab","volume":"62","author":"Habek","year":"2022","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"8","key":"10.1016\/j.msard.2026.106998_bib0010","doi-asserted-by":"crossref","DOI":"10.1111\/ene.16331","article-title":"Hypogammaglobulinaemia during rituximab treatment in multiple sclerosis: a Swedish cohort study","volume":"31","author":"Hallberg","year":"2024","journal-title":"Eur. J. Neurol."},{"issue":"3","key":"10.1016\/j.msard.2026.106998_bib0011","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000200211","article-title":"Multiple Sclerosis, Rituximab, Hypogammaglobulinemia, and Risk of Infections","volume":"11","author":"Langer-Gould","year":"2024","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"issue":"5","key":"10.1016\/j.msard.2026.106998_bib0012","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000825","article-title":"Extending rituximab dosing intervals in patients with MS during the COVID-19 pandemic and beyond?","volume":"7","author":"Maarouf","year":"2020","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"issue":"1","key":"10.1016\/j.msard.2026.106998_bib0013","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000001115","article-title":"Hypogammaglobulinemia and infections in patients with multiple sclerosis treated with rituximab","volume":"9","author":"Perriguey","year":"2022","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"10.1016\/j.msard.2026.106998_bib0014","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2023.105028","article-title":"Ocrelizumab B-cell repopulation-guided extended interval dosing versus standard dosing \u2013 similar clinical efficacy with decreased immunoglobulin M deficiency rates","volume":"79","author":"Rempe","year":"2023","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"3","key":"10.1016\/j.msard.2026.106998_bib0015","doi-asserted-by":"crossref","DOI":"10.1016\/j.neurot.2025.e00554","article-title":"Extended-interval dosing of rituximab\/ocrelizumab is associated with a reduced decrease in IgG levels in multiple sclerosis","volume":"22","author":"Rigollet","year":"2025","journal-title":"Neurotherapeutics"},{"issue":"5","key":"10.1016\/j.msard.2026.106998_bib0016","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1177\/13524585211055593","article-title":"Stable multiple sclerosis patients on anti-CD20 therapy should go on extended interval dosing\u2014\u201cYes.\u201d","volume":"28","author":"Rolfes","year":"2022","journal-title":"Mult. Scler. J."},{"issue":"5","key":"10.1016\/j.msard.2026.106998_bib0017","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000001035","article-title":"Ocrelizumab extended interval dosing in multiple sclerosis in times of COVID-19","volume":"8","author":"Rolfes","year":"2021","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"10.1016\/j.msard.2026.106998_bib0018","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2020.102472","article-title":"Evaluation of the rate of COVID-19 infection, hospitalization and death among Iranian patients with multiple sclerosis","volume":"46","author":"Sahraian","year":"2020","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"6","key":"10.1016\/j.msard.2026.106998_bib0019","doi-asserted-by":"crossref","DOI":"10.1016\/j.medj.2023.05.001","article-title":"Impact of extended interval dosing of ocrelizumab on immunoglobulin levels in multiple sclerosis","volume":"4","author":"Schuckmann","year":"2023","journal-title":"Med."},{"issue":"7","key":"10.1016\/j.msard.2026.106998_bib0020","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1177\/13524585211026272","article-title":"Increased rate of hospitalisation for COVID-19 among rituximab-treated multiple sclerosis patients: A study of the Swedish multiple sclerosis registry","volume":"28","author":"Spelman","year":"2022","journal-title":"Mult. Scler. J."},{"issue":"1","key":"10.1016\/j.msard.2026.106998_bib0021","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000200056","article-title":"Sustained low relapse rate with highly variable B-cell repopulation dynamics with extended rituximab dosing intervals in multiple sclerosis","volume":"10","author":"Starvaggi Cucuzza","year":"2023","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"issue":"5","key":"10.1016\/j.msard.2026.106998_bib0022","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1177\/13524585211064441","article-title":"Stable multiple sclerosis patients on anti-CD20 therapy should go on extended interval dosing: NO","volume":"28","author":"van Kempen Z","year":"2022","journal-title":"Mult. Scler. J."},{"issue":"12","key":"10.1016\/j.msard.2026.106998_bib0023","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1136\/jnnp-2023-333206","article-title":"Impact of previous treatment history and B-cell depletion treatment duration on infection risk in relapsing-remitting multiple sclerosis: a nationwide cohort study","volume":"95","author":"Virtanen","year":"2024","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"issue":"9","key":"10.1016\/j.msard.2026.106998_bib0024","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1002\/acn3.51136","article-title":"Serious safety events in rituximab-treated multiple sclerosis and related disorders","volume":"7","author":"Vollmer","year":"2020","journal-title":"Ann. Clin. Transl. Neurol."},{"issue":"3","key":"10.1016\/j.msard.2026.106998_bib0025","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/S1474-4422(18)30443-5","article-title":"Global, regional, and national burden of multiple sclerosis 1990\u20132016: a systematic analysis for the Global Burden of Disease Study 2016","volume":"18","author":"Wallin","year":"2019","journal-title":"Lancet Neurol."},{"issue":"14","key":"10.1016\/j.msard.2026.106998_bib0026","doi-asserted-by":"crossref","first-page":"1816","DOI":"10.1177\/1352458520970841","article-title":"Rising prevalence of multiple sclerosis worldwide: insights from the Atlas of MS, third edition","volume":"26","author":"Walton","year":"2020","journal-title":"Mult. Scler. J."},{"issue":"11","key":"10.1016\/j.msard.2026.106998_bib0027","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1007\/s40263-022-00961-x","article-title":"The efficacy and safety of anti-CD20 antibody treatments in relapsing multiple sclerosis: a systematic review and network meta-analysis","volume":"36","author":"Wu","year":"2022","journal-title":"CNS Drugs"}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034826000349?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034826000349?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T15:54:43Z","timestamp":1780415683000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211034826000349"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":27,"alternative-id":["S2211034826000349"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2026.106998","relation":{},"ISSN":["2211-0348"],"issn-type":[{"value":"2211-0348","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Extended interval dosing of off-label rituximab in multiple sclerosis: A real-world retrospective analysis of clinical efficacy and safety","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2026.106998","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"106998"}}